Fig. 4.

Proportion with EDSS progression at each year by T1 Gd + lesions at 6 months. a Placebo/delayed treatment group; b IFN β-1a 22 μg SC tiw group; c IFN β-1a 44 μg SC tiw group. There was a significant difference in the number of patients who had T1 Gd + lesions at 6 months and who experienced confirmed disability progression at 4 years in the IFN β-1a 44 μg SC tiw group, albeit in a small number of patients (n = 9). No statistically significant differences were seen in the placebo/delayed treatment or IFN β-1a 22 μg SC tiw groups. Values were based on logistic regression model adjusting for number of relapses within the previous 2 years, age, baseline EDSS score, and baseline T1 Gd + lesions. p values were calculated for the predictive effect of T1 Gd + lesions. *p < 0.05. EDSS: Expanded Disability Status Scale; Gd+: gadolinium-enhancing; IFN β-1a: interferon beta-1a; SC: subcutaneously; tiw: three times weekly